Photo of Vipul Pareek, MD

Vipul Pareek, MD

Research Area:

Expertise of Vipul Pareek, MD

3 items. To interact with these items, press Control-Option-Shift-Right Arrow
Item 1 of 3
Biography

Vipul Pareek, MD, is a highly experienced physician with triple-board certification in hematology, oncology and internal medicine. He joined AdventHealth Medical Group from Oklahoma City, where he was an award-winning physician and assistant professor at the Stephenson Cancer Center and specialized in helping patients with thoracic cancers. Prior to that time, he undertook a three-year hematology and oncology fellowship at Montefiore Medical Center/Albert Einstein College of Medicine in the Bronx. A graduate of the distinguished BJ Medical College of Gujarat University in India, he also served as Chief Fellow in the Department of Nuclear Medicine and Molecular Imaging at India’s elite Post Graduate Institute of Medical Education and Research and was awarded the Bronze Medal for Medical Excellence by the president of India in 2010.

Item 2 of 3
Education

BJ Medical College, Gujarat University, Ahmedabad, India

Item 3 of 3
Fellowship

Montefiore Medical Center/Albert Einstein College of Medicine, Bronx, NY

Publications of Vipul Pareek, MD
  • Exosomes as drug delivery vehicle and contributor of resistance to anticancer drugs
    , CANCER LETTERS

  • Progress in extracellular vesicle biology and their application in cancer medicine
    , WILEY INTERDISCIPLINARY REVIEWS-NANOMEDICINE AND NANOBIOTECHNOLOGY

  • Predictors of Outcome in Patients With Fibrolamellar Carcinoma: Analysis of the National Cancer Database
    , ANTICANCER RESEARCH

    More sources loaded

  • Surgery Versus Surveillance for Well-Differentiated, Nonfunctional Pancreatic Neuroendocrine Tumors: An 11-Year Analysis of the National Cancer Database
    , ONCOLOGIST

  • Marked Differences in CNS Activity among EGFR Inhibitors: Case Report and Mini-Review
    , JOURNAL OF THORACIC ONCOLOGY

  • Immune checkpoint blockade in human cancer therapy: lung cancer and hematologic malignancies
    , IMMUNOTHERAPY

  • Emerging treatment for ALK-positive lung cancer
    , EXPERT OPINION ON EMERGING DRUGS